Biofrontera cancels admission of shares on AIM

Dermatology company Biofrontera on Wednesday said it was cancelling its admission of ordinary shares to trading on London Stock Exchange’s AIM index from 18 February.

The decision to cancel its shares on AIM follows a review by the board which showed a “very low volume of trading” on the index, the company said in a statement.

The board concluded that the costs of maintaining a secondary listing on AIM exceeded the benefits of the listing.

The group will continue to operate on the Frankfurt Stock Exchange.